Multiple Myeloma Diagnosis
See also: Multiple Myeloma Differential DiagnosisHave all of the relevant analysis carried out numerous myeloma, it is very important, since the results of the tests help the doctor to better define treatment options and prognosis. Many of these tests are used to evaluate the extent of the disease and to plan and monitor the treatment.
Multiple Myeloma Diagnosis: Get a Second Opinion
Once your doctor has diagnosed with multiple myeloma, it is important that you consult an expert experienced in treating myeloma to further evaluate your disease and help develop a treatment plan. Many health insurance companies will authorize a second opinion-check with you.The MMRF can help you find the National Cancer Institute (NCI) Cancer Center-Locations or myeloma specialist in your area. People with myeloma often devote themselves to a Haematology / Oncology.
Genomic Test
Researchers are constantly working to better understand the biology of multiple myeloma, as the expense of genomics (study of DNA of tumor cells) research, we have learned that there are many variations in the DNA of myeloma cells. The ultimate goal of the genomic research and develop an individual treatment on the basis of DNA in the myeloma cells of individual patients.
See also: Multiple Myeloma Diagnosis CriteriaTests with the analysis of the genomic DNA of myeloma cells taken from a small amount of bone marrow. The tests were carried out in the primary diagnosis and may be repeated periodically. The most common tests are the karyotype and the fish. Other tests more sensitive, are used in research, and begin to use them, as well, in some cancer centers.
To date there is no evidence that the myeloma is inherited, and the changes in the DNA, most probably due to mutations in the cells that occur in patients with the time. While certain modifications of the DNA indicate how the myeloma is aggressive, patients with changes in the DNA do not necessarily have a worse prognosis.
Although there is limited information on the genomic analysis to make treatment decisions, with several notable exceptions, such as the change of the t-DNA (4; 14) chromosomal abnormalities. Studies have shown that patients with t (4; 14) have better outcomes when treated with a proteasome inhibitor such as Velcade®. Given that researchers still have not found any reason to believe that multiple myeloma is a hereditary, genetic testing is not recommended for members of the family.
See also: Multiple Myeloma Stages Life Expectancy